CN107532176A - 核酸构建体 - Google Patents

核酸构建体 Download PDF

Info

Publication number
CN107532176A
CN107532176A CN201680024069.5A CN201680024069A CN107532176A CN 107532176 A CN107532176 A CN 107532176A CN 201680024069 A CN201680024069 A CN 201680024069A CN 107532176 A CN107532176 A CN 107532176A
Authority
CN
China
Prior art keywords
leu
glu
asp
intracellular
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680024069.5A
Other languages
English (en)
Chinese (zh)
Inventor
M.普莱
S.科多巴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of CN107532176A publication Critical patent/CN107532176A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201680024069.5A 2015-04-27 2016-04-26 核酸构建体 Pending CN107532176A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1507104.6A GB201507104D0 (en) 2015-04-27 2015-04-27 Nucleic acid construct
GB1507104.6 2015-04-27
PCT/GB2016/051164 WO2016174408A1 (en) 2015-04-27 2016-04-26 Nucleic acid construct

Publications (1)

Publication Number Publication Date
CN107532176A true CN107532176A (zh) 2018-01-02

Family

ID=53488689

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680024069.5A Pending CN107532176A (zh) 2015-04-27 2016-04-26 核酸构建体

Country Status (10)

Country Link
US (1) US11530420B2 (enExample)
EP (1) EP3288968B1 (enExample)
JP (2) JP6836515B2 (enExample)
CN (1) CN107532176A (enExample)
AU (1) AU2016254498B2 (enExample)
CA (1) CA2984101A1 (enExample)
ES (1) ES2847698T3 (enExample)
GB (1) GB201507104D0 (enExample)
HK (1) HK1244021A1 (enExample)
WO (1) WO2016174408A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138201A (zh) * 2015-09-04 2018-06-08 托卡根公司 包含2a肽的重组载体
CN108359014A (zh) * 2018-02-08 2018-08-03 四川农业大学 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3143134B1 (en) 2014-05-15 2020-10-28 National University of Singapore Modified natural killer cells and uses thereof
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
SG10201912387PA (en) 2016-11-22 2020-02-27 Nat Univ Singapore Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
WO2018175988A1 (en) * 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
SG11201908492PA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3601537A4 (en) 2017-03-27 2021-01-13 National University of Singapore STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS
EP3700561A1 (en) * 2017-10-27 2020-09-02 Statens Serum Institut A polygene influenza vaccine
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
KR20200138741A (ko) 2018-04-02 2020-12-10 내셔널 유니버시티 오브 싱가포르 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화
GB201805918D0 (en) * 2018-04-10 2018-05-23 Autolus Ltd Cell
US20220175960A1 (en) * 2018-08-24 2022-06-09 Locanabio, Inc. Fasl immunomodulatory gene therapy compositions and methods for use
JP7560882B2 (ja) 2018-08-29 2024-10-03 ナショナル ユニヴァーシティー オブ シンガポール 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
WO2024197792A1 (en) * 2023-03-31 2024-10-03 Beijing University Of Chinese Medicine A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185552A1 (zh) * 2012-06-12 2013-12-19 中国人民解放军第二军医大学东方肝胆外科医院 双信号独立的嵌合抗原受体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
US20070065912A1 (en) * 2005-07-21 2007-03-22 Abbott Laboratories Multiple Gene Expression including sORF Constructs and Methods with Polyproteins, Pro-Proteins, and Proteolysis
MX2015006301A (es) * 2012-11-21 2015-09-07 Merz Pharma Gmbh & Co Kgaa Medios y metodos para la determinacion de la actividad biologica de la neurotoxina botulinica.
CN106132423B (zh) * 2014-02-14 2020-07-31 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
WO2016123010A1 (en) 2015-01-26 2016-08-04 United States Mineral Products Company Corrosion resistant spray applied fire resistive materials

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013185552A1 (zh) * 2012-06-12 2013-12-19 中国人民解放军第二军医大学东方肝胆外科医院 双信号独立的嵌合抗原受体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMRANI,A.E. ET AL: "Coordinate Expression and Independents Subcellular Targeting of multiple Proteins from a single Transgene", 《PLANT PHYSIOLOGY》 *
PELHAM,HUGH R.B: "Using Sorting signal retain Proteins in Endoplasmic Reticulum", 《METHODS IN ENZYMOLOGY》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108138201A (zh) * 2015-09-04 2018-06-08 托卡根公司 包含2a肽的重组载体
CN108359014A (zh) * 2018-02-08 2018-08-03 四川农业大学 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法

Also Published As

Publication number Publication date
EP3288968B1 (en) 2020-11-25
EP3288968A1 (en) 2018-03-07
WO2016174408A1 (en) 2016-11-03
JP2018514208A (ja) 2018-06-07
US11530420B2 (en) 2022-12-20
US20180100163A1 (en) 2018-04-12
JP2020171313A (ja) 2020-10-22
GB201507104D0 (en) 2015-06-10
ES2847698T3 (es) 2021-08-03
CA2984101A1 (en) 2016-11-03
JP6836515B2 (ja) 2021-03-03
HK1244021A1 (zh) 2018-07-27
AU2016254498B2 (en) 2020-10-22
AU2016254498A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
CN107532176A (zh) 核酸构建体
US11613559B2 (en) Nucleic acid construct
ES2778905T3 (es) Constructo de ácido nucleico para la expresión de más de un receptor de antígeno quimérico
EP3288970B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
WO2016174407A1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
CN114555789A (zh) 工程化免疫细胞
MX2012009942A (es) Vector de expresion.
US20180371056A1 (en) Multi-Span Chimeric Antigen Receptor
WO2022167798A1 (en) Molecule
KR100843634B1 (ko) 세포막투과 전달 펩타이드 및 이를 포함하는 생물제제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: England Atsushi

Applicant after: UCL business Limited

Address before: England Atsushi

Applicant before: UCL Business Co., Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20201127

Address after: England Atsushi

Applicant after: AUTOLUS Ltd.

Address before: England Atsushi

Applicant before: UCL business Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102

WD01 Invention patent application deemed withdrawn after publication